Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab Plus Radiotherapy vs Radiotherapy Alone in Postoperative Intermediate-Risk LA-HNSCC
ChiCTR2600125401Phase 3Recruiting
- Sponsor
- First Affiliated Hospital of Xi'an Jiaotong University
- Start
- May 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nimotuzumab in head and neck squamous cell carcinoma (HNSCC), mouth cancer, oropharyngeal cancer and 2 more (2 arms), sponsored by First Affiliated Hospital of Xi'an Jiaotong University. Primary endpoint: 3-year disease-free survival rate. Started May 2026; status: recruiting.
02
Drugs
nimotuzumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)mouth canceroropharyngeal cancerhypopharyngeal cancerlaryngeal cancer
Beyond the preview
Go deeper on ChiCTR2600125401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600125401.